Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

A single center experience

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim. Pseudomyxoma peritonei PMP is a rare form of peritoneal carcinomatosis characterized by abnormal quantity of extracellular mucinous material. It almost originates from a primary appendiceal tumor with different malignancy degrees. The purpose of this study was to evaluate outcome and longterm survival on 80 patients affected by PMP after cytoreductive surgery CRS associated with hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. From October 1995 to June 2012, about 550 operations for PC were performed; in 300 cases surgical cytoreduction in association with HIPEC was carried out. Regarding PMP, 80 procedures of CRS and HIPEC were performed. This approach is based on surgical removal of the primitive cancer, peri-tonectomy (stripping of implants on the peri-toneal surface) and HIPEC performed with cisplatinum and C mytomicin. The rationale of this treatment is to obtain, after macroscopic disease removal, an elevated and persistent drug concentration in the peritoneal cavity, with limited systemic effects. Results. The complication rate was 52.5% (42/80) with no postoperative deaths. The median overall and progression-free survival were 144 and 88 months, respectively. Not complete cytoreductive surgery (P

Original languageEnglish
Pages (from-to)569-577
Number of pages9
JournalMinerva Chirurgica
Volume68
Issue number6
Publication statusPublished - Dec 2013

Fingerprint

Pseudomyxoma Peritonei
Drug Therapy
Neoplasms
Peritoneal Cavity
Therapeutics
Disease-Free Survival
Carcinoma
Survival
Pharmaceutical Preparations

Keywords

  • Carcinoma
  • Malignant hyperthermia.
  • Pseudomyxoma peritonei

ASJC Scopus subject areas

  • Surgery

Cite this

@article{6833f3ae829e45419c0976eadfd67328,
title = "Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): A single center experience",
abstract = "Aim. Pseudomyxoma peritonei PMP is a rare form of peritoneal carcinomatosis characterized by abnormal quantity of extracellular mucinous material. It almost originates from a primary appendiceal tumor with different malignancy degrees. The purpose of this study was to evaluate outcome and longterm survival on 80 patients affected by PMP after cytoreductive surgery CRS associated with hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. From October 1995 to June 2012, about 550 operations for PC were performed; in 300 cases surgical cytoreduction in association with HIPEC was carried out. Regarding PMP, 80 procedures of CRS and HIPEC were performed. This approach is based on surgical removal of the primitive cancer, peri-tonectomy (stripping of implants on the peri-toneal surface) and HIPEC performed with cisplatinum and C mytomicin. The rationale of this treatment is to obtain, after macroscopic disease removal, an elevated and persistent drug concentration in the peritoneal cavity, with limited systemic effects. Results. The complication rate was 52.5{\%} (42/80) with no postoperative deaths. The median overall and progression-free survival were 144 and 88 months, respectively. Not complete cytoreductive surgery (P",
keywords = "Carcinoma, Malignant hyperthermia., Pseudomyxoma peritonei",
author = "M. Robella and M. Vaira and P. Marsanic and A. Mellano and A. Cinquegrana and A. Sottile and {De Simone}, M.",
year = "2013",
month = "12",
language = "English",
volume = "68",
pages = "569--577",
journal = "Minerva Chirurgica",
issn = "0026-4733",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

T2 - A single center experience

AU - Robella, M.

AU - Vaira, M.

AU - Marsanic, P.

AU - Mellano, A.

AU - Cinquegrana, A.

AU - Sottile, A.

AU - De Simone, M.

PY - 2013/12

Y1 - 2013/12

N2 - Aim. Pseudomyxoma peritonei PMP is a rare form of peritoneal carcinomatosis characterized by abnormal quantity of extracellular mucinous material. It almost originates from a primary appendiceal tumor with different malignancy degrees. The purpose of this study was to evaluate outcome and longterm survival on 80 patients affected by PMP after cytoreductive surgery CRS associated with hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. From October 1995 to June 2012, about 550 operations for PC were performed; in 300 cases surgical cytoreduction in association with HIPEC was carried out. Regarding PMP, 80 procedures of CRS and HIPEC were performed. This approach is based on surgical removal of the primitive cancer, peri-tonectomy (stripping of implants on the peri-toneal surface) and HIPEC performed with cisplatinum and C mytomicin. The rationale of this treatment is to obtain, after macroscopic disease removal, an elevated and persistent drug concentration in the peritoneal cavity, with limited systemic effects. Results. The complication rate was 52.5% (42/80) with no postoperative deaths. The median overall and progression-free survival were 144 and 88 months, respectively. Not complete cytoreductive surgery (P

AB - Aim. Pseudomyxoma peritonei PMP is a rare form of peritoneal carcinomatosis characterized by abnormal quantity of extracellular mucinous material. It almost originates from a primary appendiceal tumor with different malignancy degrees. The purpose of this study was to evaluate outcome and longterm survival on 80 patients affected by PMP after cytoreductive surgery CRS associated with hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. From October 1995 to June 2012, about 550 operations for PC were performed; in 300 cases surgical cytoreduction in association with HIPEC was carried out. Regarding PMP, 80 procedures of CRS and HIPEC were performed. This approach is based on surgical removal of the primitive cancer, peri-tonectomy (stripping of implants on the peri-toneal surface) and HIPEC performed with cisplatinum and C mytomicin. The rationale of this treatment is to obtain, after macroscopic disease removal, an elevated and persistent drug concentration in the peritoneal cavity, with limited systemic effects. Results. The complication rate was 52.5% (42/80) with no postoperative deaths. The median overall and progression-free survival were 144 and 88 months, respectively. Not complete cytoreductive surgery (P

KW - Carcinoma

KW - Malignant hyperthermia.

KW - Pseudomyxoma peritonei

UR - http://www.scopus.com/inward/record.url?scp=84891601127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891601127&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 569

EP - 577

JO - Minerva Chirurgica

JF - Minerva Chirurgica

SN - 0026-4733

IS - 6

ER -